Associated Papers
Development and validation of a mutation-based model to predict immunotherapeutic efficacy in NSCLC.
He P et al.
Frontiers in Oncology, 2023
36910641 (PubMed )
Supplement: DataSheet_1.xlsx › Table_S8
Genetic variants and normal tissue toxicity after radiotherapy: a systematic review.
Andreassen CN et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology, 2009
Genetic markers for prediction of normal tissue toxicity after radiotherapy.
Alsner J et al.
Seminars in Radiation Oncology, 2008
Pharmacogenetics for individualized cancer chemotherapy.
Efferth T et al.
Pharmacology & Therapeutics, 2005
Can risk of radiotherapy-induced normal tissue complications be predicted from genetic profiles?
Andreassen CN
Acta Oncologica (stockholm, Sweden), 2005
Novel DNA sequence variants in the hHR21 DNA repair gene in radiosensitive cancer patients.
Severin DM et al.
International Journal of Radiation Oncology, Biology, Physics, 2001
Select a paper to view details